RAC

2.11%

$1.45 race oncology ltd

Medical / Clinical Discussions, page-497

First 497 Last

Share
Profile

Follow
KingBuzzo

386 Posts.

888

17/06/21

14:01

Post #: 53900636
Share

Originally posted by RaceOncology: ↑

1. Yes this “repatenting" strategy has been used before - a good example of this is CPX-351 (Vyxeos) which is just two old generic drugs (doxorubicin and ara-c) in a liposome. This was sold to Jazz for around US$2 billion.

2. Yes this is correct and is one of the major reasons we continue to spend resources on developing and patenting new IP around manufacturing, formulation and use. Of course it is possible that someone will work around our patents, but in someways this is self defeating. As a pharma company you want exclusivity, not a price war. What can prevent this from even being considered as an option is orphan drug designation.

3. Orphan drug designation provides 7 years post approval (i.e. after you start selling) exclusivity (even if you have no patent what so ever) in the USA and 10 years in the EU. By pursuing a rapid path to approval in an orphan indication (AML) we can head off anyone even attempting to try and work around our patents as they would be locked out of selling the drug for 7 to 10 years. If you couldn’t sell a drug for 10 years why would you expend money and effort on trying to make Bisantrene?

Ultimately I see the competition coming from completely new FTO inhibitors. The real value of Bisantrene is the huge amount of clinical data (and manufacturing) we have that gives us a jump on all the new FTO inhibitors that will be developed. Just like was seen with Keytruda, being first can give you a really strong market position even when faced with lots of competition (there are now 7 different anti-PD-1/PD-L1 drugs on the market). Keyruda doesn’t sell $10s of billion a year because it is the only choice, but because clinicians are familiar with it.

Expand

Thanks again for your quick response. It's very reassuring that there's a solid strategy that can be summarized so succinctly. I assumed this was the case of course, but just couldn't find all the pieces at the time...

RAC Price at posting: $3.71 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

HotCopper Highlights: Your most watched stocks for Week 46, 2024

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

First 497 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.45		Change 0.030(2.11%)		Mkt cap ! $247.1M

Open	High	Low	Value	Volume
$1.43	$1.45	$1.40	$163.8K	115.3K

Buyers (Bids)

No.	Vol.	Price($)
1	500	$1.44

Sellers (Offers)

Price($)	Vol.	No.
$1.45	31396	1

View Market Depth

No.	Vol.	Price($)
1	500	1.440
1	11250	1.390
1	1000	1.380
1	5000	1.370
1	1279	1.365

Price($)	Vol.	No.
1.450	31396	1
1.480	3055	2
1.500	17040	2
1.520	6000	1
1.575	2000	1

Last trade - 16.10pm 15/11/2024 (20 minute delay)

RAC (ASX) Chart

Medical / Clinical Discussions, page-497

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

HotCopper Highlights: Your most watched stocks for Week 46, 2024

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Banshee's historic trenches prove rich in antimony and gold for GDM

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Medical / Clinical Discussions, page-497

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

HotCopper Highlights: Your most watched stocks for Week 46, 2024

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Banshee's historic trenches prove rich in antimony and gold for GDM

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News